首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   1021篇
  免费   28篇
  国内免费   19篇
耳鼻咽喉   2篇
儿科学   4篇
妇产科学   7篇
基础医学   114篇
口腔科学   18篇
临床医学   58篇
内科学   104篇
皮肤病学   26篇
神经病学   38篇
特种医学   50篇
外国民族医学   1篇
外科学   16篇
综合类   78篇
现状与发展   1篇
预防医学   30篇
眼科学   5篇
药学   425篇
中国医学   24篇
肿瘤学   67篇
  2023年   7篇
  2022年   10篇
  2021年   17篇
  2020年   11篇
  2019年   10篇
  2018年   16篇
  2017年   13篇
  2016年   9篇
  2015年   19篇
  2014年   41篇
  2013年   49篇
  2012年   60篇
  2011年   99篇
  2010年   82篇
  2009年   66篇
  2008年   63篇
  2007年   53篇
  2006年   49篇
  2005年   60篇
  2004年   55篇
  2003年   57篇
  2002年   31篇
  2001年   26篇
  2000年   21篇
  1999年   9篇
  1998年   11篇
  1997年   7篇
  1996年   8篇
  1995年   4篇
  1994年   8篇
  1993年   2篇
  1992年   5篇
  1991年   2篇
  1990年   9篇
  1989年   4篇
  1988年   5篇
  1987年   6篇
  1986年   2篇
  1985年   8篇
  1984年   10篇
  1983年   9篇
  1982年   10篇
  1981年   6篇
  1980年   2篇
  1979年   3篇
  1978年   2篇
  1977年   3篇
  1975年   2篇
  1973年   3篇
  1971年   1篇
排序方式: 共有1068条查询结果,搜索用时 687 毫秒
11.
Quinolin-2-one represents an important and valuable chemical motif that possesses a wide variety of biological activities; however, the anti-influenza activities of quinolin-2-one-containing compounds were rarely reported. Herein, we describe the screening and identification of 3-aryl-quinolin-2-one derivatives as a novel class of antiviral agents. The 3-aryl-quinolinone derivatives were synthesized via an efficient copper-catalyzed reaction cascade that we previously developed. Using this synthetic method, preliminary structure–activity relationships of this scaffold against the influenza A virus infection were systematically explored. The most potent compound 34 displayed IC50 values of 2.14 and 4.88 μM against the replication of H3N2 (A/HK/8/68) and H1N1 (A/WSN/33) strains, respectively, without apparent cytotoxicity on MDCK cells. We further demonstrated that 27 and 34 potently inhibited the plaque formation of the IAV, rendering this scaffold attractive for pursuing novel anti-influenza agents.  相似文献   
12.
A new approach for 11C–C bond formation via a Sonogashira‐like cross‐coupling reaction of terminal alkynes with [11C]methyl iodide was exemplified by the synthesis of 17α‐(3′‐[11C]prop‐1‐yn‐1‐yl)‐3‐methoxy‐3,17β‐estradiol. The LC‐purified title compound was obtained in decay‐corrected radiochemical yields of 27–47% (n=8) based on [11C]methyl iodide within 21–27 min after EOB. In a typical synthesis starting from 9.6 GBq [11C]methyl iodide, 1.87 GBq of 17α‐(3′‐[11C]prop‐1‐yn‐1‐yl)‐3‐methoxy‐3,17β‐estradiol was synthesized in radiochemical purity >99%. The specific radioactivity ranged between 10 and 19 GBq/µmol, and the labeling position was verified by 13C‐NMR analysis of the corresponding 13C‐labeled compound. Copyright © 2003 John Wiley & Sons, Ltd.  相似文献   
13.
In a 2-year carcinogenicity study of potassium iodide (KI) in F344/DuCrj rats, squamous cell carcinomas (SCCs) were observed in the salivary glands of 4/40 males and 3/40 females receiving 1000 ppm KI in the drinking water. Ductular proliferation with lobular atrophy was observed at high incidence in the submandibular glands of the high-dose animals, and squamous metaplasia was frequently evident within the proliferative ductules and the larger interlobular ducts. A transition from metaplasia to SCC was apparent. The results suggest that squamous metaplasia in proliferative ductules, occurring secondarily to lobular impairment induced by KI, may develop into SCCs via a non-genotoxic, proliferation-dependent mechanism.  相似文献   
14.
Detection of perchlorate (ClO4-) in several drinking water sources across the U.S. has lead to public concern over health effects from chronic low-level exposures. Perchlorate inhibits thyroid iodide (I-) uptake at the sodium (Na+)-iodide (I-) symporter (NIS), thereby disrupting the initial stage of thyroid hormone synthesis. A physiologically based pharmacokinetic (PBPK) model was developed to describe the kinetics and distribution of both radioactive I- and cold ClO4- in healthy adult humans and simulates the subsequent inhibition of thyroid uptake of radioactive I- by ClO4-. The model successfully predicts the measured levels of serum and urinary ClO4- from drinking water exposures, ranging from 0.007 to 12 mg ClO4-/kg/day, as well as the subsequent inhibition of thyroid 131I- uptake. Thyroid iodine, as well as total, free, and protein-bound radioactive I- in serum from various tracer studies, are also successfully simulated. This model's parameters, in conjunction with corresponding model parameters established for the male, gestational, and lactating rat, can be used to estimate parameters in a pregnant or lactating human, that have not been or cannot be easily measured to extrapolate dose metrics and correlate observed effects in perchlorate toxicity studies to other human life stages. For example, by applying the adult male rat:adult human ratios of model parameters to those parameters established for the gestational and lactating rat, we can derive a reasonable estimate of corresponding parameters for a gestating or lactating human female. Although thyroid hormones and their regulatory feedback are not incorporated in the model structure, the model's successful prediction of free and bound radioactive I- and perchlorate's interaction with free radioactive I- provide a basis for extending the structure to address the complex hypothalamic-pituitary-thyroid feedback system. In this paper, bound radioactive I- refers to I- incorporated into thyroid hormones or iodinated proteins, which may or may not be bound to plasma proteins.  相似文献   
15.
目的研究碘化N正丁基氟哌啶醇(F2)对豚鼠心房肌细胞乙酰胆碱敏感性钾通道(KACh)的影响,探讨其对KACh的作用机制。方法采用膜片钳全细胞记录方法,测定F2对原代培养的豚鼠心房肌细胞乙酰胆碱敏感性钾电流IK(ACh)的影响。结果细胞外给予F2对豚鼠心房肌细胞IK(ACh)呈可逆性、浓度依赖性的阻断作用。细胞内添入抗水解的GTP类似物GTPγS后,结果同前。细胞内给予50μmol·L-1F2对IK(ACh)无作用。结论F2是豚鼠心房肌细胞KACh的一种快速通道阻断剂,发挥作用部位在细胞膜外侧,作用位点在钾通道本身,与乙酰胆碱受体无关。  相似文献   
16.
The use of potassium iodide (KI) as a protective agent against accidental radioactive exposure is well established. In this study, we aimed to prepare a KI tablet formulation using a direct compression method. We utilized Design of Experiment (DoE)/mixture design to define the best formulation with predetermined physical qualities as to its dissolution, hardness, assay, disintegration, and angle of repose. Based on the results from the DoE, the formulation had the following components (%w/w): Avicel 48.70%, silicon dioxide 0.27%, stearic acid (1.00%), magnesium stearate 2.45%, and dicalcium phosphate 18.69%, in addition to potassium iodide 28.89% (130 mg/tablet). This formulation was scaled-up using two tablet presses, a single-punch press and a rotary mini tablet press. The final scaled-up formulation was subjected to a variety of quality control tests, including photo-stability testing. The results indicate that potassium iodide tablets prepared by a rotary mini tablet press had good pharmaceutical characteristics and a shelf-life of 25 days when stored at room temperature protected from light.  相似文献   
17.
《药学学报(英文版)》2020,10(2):327-343
Our recent studies demonstrated that the natural product nobiletin (NOB) served as a promising multidrug resistance (MDR) reversal agent and improved the effectiveness of cancer chemotherapy in vitro. However, low aqueous solubility and difficulty in total synthesis limited its application as a therapeutic agent. To tackle these challenges, NOB was synthesized in a high yield by a concise route of six steps and fourteen derivatives were synthesized with remarkable solubility and efficacy. All the compounds showed improved sensitivity to paclitaxel (PTX) in P-glycoprotein (P-gp) overexpressing MDR cancer cells. Among them, compound 29d exhibited water solubility 280-fold higher than NOB. A drug-resistance A549/T xenograft model showed that 29d, at a dose of 50 mg/kg co-administered with PTX (15 mg/kg), inhibited tumor growth more effective than NOB and remarkably increased PTX concentration in the tumors via P-gp inhibition. Moreover, Western blot experiments revealed that 29d inhibited expression of NRF2, phosphorylated ERK and AKT in MDR cancer cells, thus implying 29d of multiple mechanisms to reverse MDR in lung cancer.  相似文献   
18.
Renal dysfunction is closely associated with endothelial damage leading to cardiovascular disease. However, the extent to which endothelial damage induced by uremia is modulated by aging is poorly known. Aging can render endothelial cells more susceptible to apoptosis through an oxidative stress-dependent pathway. We examined whether senescence-associated to oxidative stress determines the injury induced by the uremia in endothelial cells.  相似文献   
19.
Oxidative stress plays an important role in the pathogenesis of Parkinson’s disease (PD). Salidroside (SAL), a phenylpropanoid glycoside isolated from Rhodiola rosea L., can exert potent antioxidant properties. In this study, we investigated the protective effects, and the possible mechanism of action, of SAL against 1-methyl-4-phenylpyridinium (MPP+)-induced cell damage in rat adrenal pheochromocytoma PC12 cells. Pretreatment of PC12 cells with SAL significantly reduced the ability of MPP+ to induce apoptosis in a dose and time-dependent manner. SAL significantly and dose-dependently inhibited MPP+-induced chromatin condensation and MPP+-induced release of lactate dehydrogenase by PC12 cells. SAL enhanced Akt phosphorylation in PC12 cells, and the protective effects of SAL against MPP+-induced apoptosis were abolished by LY294002, a specific inhibitor of phosphatidylinositol 3-kinase (PI3K) phosphorylation. These findings suggest that SAL prevents MPP+-induced apoptosis in PC12 cells, at least in part through activation of the PI3K/Akt pathway.  相似文献   
20.
碘酸钾、碘化钾对小鼠甲状腺形态结构和功能的影响   总被引:1,自引:1,他引:1  
目的 用接近于流行病现场调查的碘水平复制小鼠动物模型,研究不同碘剂对小鼠甲状腺形态结构和功能的影响。方法 将小鼠按体重随机分为基础饲料组(NG)、适碘酸钾组(NO)、高碘酸钾组(HO)、高碘化钾组(HI),喂养90d后,测定甲状腺重量、血清甲状腺激索、尿碘水平,在光镜和电镜下观察甲状腺形态结构的变化。结果 100μg/L的水碘即可导致小鼠胶质样甲状腺肿,使甲状腺绝对重量和相对重量增加;与NG组比较,HO组和HI组血清Td、尿碘水平上升,血清B水平无明显变化;HO组尿碘水平高于HI组;NO组与NG组比较,除尿碘水平上升外,其余各项指标无明显变化。结论 当饮水中碘浓度为100μg/L时,碘酸钾与碘化钾均可引起小鼠甲状腺肿大和甲状腺功能改变,两者无明显不同;小鼠对碘酸钾的利用率低于对碘化钾的利用率。  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号